TScan Therapeutics' TSC-101 Shows Positive Phase 1 Data, Paving Way for Pivotal Phase 3 Study
TCRX sits 19% above its 52-week low of $0.848.
Summary
TScan Therapeutics announced positive initial data from Cohort C of its Phase 1 ALLOHA™ study for TSC-101 in patients with heme malignancies. The data showed 11 of 14 patients achieved complete donor chimerism within approximately three weeks, and the therapy was well-tolerated. This strong Phase 1 outcome directly supports the company's plan to initiate a pivotal Phase 3 study for TSC-101 this month, a significant de-risking event for their lead candidate. This follows the company's Q1 update on May 6th, which highlighted the planned Phase 3 initiation, and recent shareholder approval to double authorized common stock, potentially preparing for future capital raises. The company is hosting a KOL event today to discuss these results and the path forward.
At the time of this announcement, TCRX was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.1M. The 52-week trading range was $0.85 to $2.57. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.